Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.
Risk factors for cytokine release syndrome and neurotoxicity identified in patients treated with epcoritamab or glofitamab, suggesting tailored management may improve safety.
Key Points
CRS of any grade occurred in 39% of patients treated with BsAb, indicating significant risk in large B cell lymphoma cases.
Prior CAR-T therapy increased CRS risk, with 63% of patients experiencing grade 1 or higher toxicity.
Observational analysis across multiple centers revealed critical risk factors associated with CRS and ICANS.
Findings support the need for predictive models to identify high-risk patients undergoing bispecific antibody therapy.